Invention Grant
- Patent Title: Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders
-
Application No.: US17322486Application Date: 2021-05-17
-
Publication No.: US11692040B2Publication Date: 2023-07-04
- Inventor: John M. Lincecum , Bingbing Jiang , Steven N. Perrin , Alan Gill , Cynthia A. Gill , Fernando G. Vieira
- Applicant: ALS Therapy Development Institute
- Applicant Address: US MA Cambridge
- Assignee: ALS THERAPY DEVELOPMENT INSTITUTE
- Current Assignee: ALS THERAPY DEVELOPMENT INSTITUTE
- Current Assignee Address: US MA Cambridge
- Agency: Knobbe, Martens, Olson & Bear, LLP
- The original application number of the division: US15931315 2020.05.13
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00 ; C07K16/28 ; A61K45/06
Abstract:
Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
Public/Granted literature
- US20210269538A1 ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERS Public/Granted day:2021-09-02
Information query
